• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Percentage of written meeting responses that were sent greater than two FDA business days in advance of the meeting (1)

Dictionary: This measure focuses on the timeliness of providing written responses to pre-meeting questions that are submitted by sponsors before a scheduled face-to-face meeting. OBRR's goal is to provide comprehensive responses prior to the meeting to further advance the exchange of information leading to more efficient product development.

Information is current as of September 30, 2012

Fiscal Year - 2011

Skip graphic and jump to text data

TimeTargetPercent
Oct 20107593
Nov 201075100
Dec 20107580
Jan 201175100
Feb 20117560
Mar 20117560
Apr 20117560
May 20117547
Jun 20117567
Jul 20117571
Aug 20117578
Sep 20117575

FY 2011 Overall: 73%

Footnotes

  • (1) FDA business days are Monday through Friday.

Number of written meeting responses during the month that were faxed/emailed greater than two FDA business days in advance of the meeting

Fiscal Year - 2011
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2010N/A13
Nov 2010N/A11
Dec 2010N/A4
Jan 2011N/A3
Feb 2011N/A3
Mar 2011N/A3
Apr 2011N/A6
May 2011N/A9
Jun 2011N/A4
Jul 2011N/A5
Aug 2011N/A7
Sep 2011N/A9

FY 2011 Total: 77

Number of written meeting responses during the month that were faxed/emailed two FDA business days or less in advance of the meeting

Fiscal Year - 2011
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2010N/A1
Nov 2010N/A0
Dec 2010N/A1
Jan 2011N/A0
Feb 2011N/A2
Mar 2011N/A2
Apr 2011N/A4
May 2011N/A10
Jun 2011N/A2
Jul 2011N/A2
Aug 2011N/A2
Sep 2011N/A3

FY 2011 Total: 29

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.